Aurobindo Pharma Ltd has acquired a US FDA compliant cGMP facility in Dayton, New Jersey.

The facility is spread over 20 acres of free hold land and is located in the heart of Princeton Life Sciences Corridor in the state of New Jersey. The campus is comprised of 100,000 square feet of fully integrated state of the art R&D, Formulation manufacturing and distribution facilities with potential for future expansion. This facility will serve as the company's US head quarters.

Ramprasad Reddy, chairman, said that this purchase reinforces Aurobindo's commitment to serve US market in an effective manner.

The company has recently concluded zero percent, foreign currency convertible bonds issue of US $ 200 million. Part of the proceeds will be used for the purchase.